Trial Profile
An Open-Label, Sequential Design Study to Assess the Effect of Rifampin on the Pharmacokinetics of PCI-32765 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Rifampicin
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Multiple myeloma; Tuberculosis
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 24 Jan 2013 New trial record
- 01 Jan 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.